Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy
- PMID: 15126146
- DOI: 10.1016/j.ajo.2003.11.079
Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy
Abstract
Purpose: To evaluate the early changes in retinal function after photodynamic therapy (PDT) by multifocal electroretinogram (mfERG).
Design: Prospective interventional case series.
Methods: Seventeen eyes from 17 patients scheduled for standard PDT with verteporfin were prospectively recruited. Patients' diagnoses included choroidal neovascularization (CNV) secondary to age-related macular degeneration, idiopathic CNV, myopic CNV, polypoidal choroidal vasculopathy, and central serous chorioretinopathy. Serial mfERG recordings were performed before PDT, and at 4 days, 2 weeks, and 1 month after PDT. The first-order kernel N1 and P1 mfERG response from the central 0 to 7 degrees and peripheral 7 to 25 degrees were grouped and analyzed. The mean response amplitudes and peak latencies of the mfERG recordings were compared longitudinally.
Results: There were statistically significant reductions in the mean N1 response amplitude for the central group at 4 days (P =.007) and 2 weeks after PDT (P =.024), in the mean P1 response amplitude for both the central (P =.006) and peripheral (P =.013) groups at 4 days, and for the central group at 2 weeks after PDT (P =.017). There were also statistically significant increases in the mean P1 response latencies at 4 days (P =.004) and at 2 weeks (P =.018) after PDT for the central group and at 4 days after PDT (P =.026) for the peripheral group. At 1 month after PDT, no significant differences in the N1 and P1 mean response amplitudes and peak latencies were observed compared with pre-PDT mfERG.
Conclusions: Transient impairments in retinal function for as long as 2 weeks after PDT were noticed by reduction in response amplitudes and a delay in peak latencies of mfERG. These findings may explain the common adverse event of subjective visual disturbance early after PDT with normal findings in visual acuity and ophthalmoscopy.
Comment in
-
Transient visual disturbance after photodynamic therapy.Am J Ophthalmol. 2005 Apr;139(4):748-9; author reply 749. doi: 10.1016/j.ajo.2004.08.072. Am J Ophthalmol. 2005. PMID: 15808191 No abstract available.
Similar articles
-
Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy.Br J Ophthalmol. 2006 Dec;90(12):1524-30. doi: 10.1136/bjo.2006.092783. Epub 2006 Jul 6. Br J Ophthalmol. 2006. PMID: 16825279 Free PMC article.
-
Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial.Retina. 2011 Jul-Aug;31(7):1378-86. doi: 10.1097/FTD.0b013e31820beb02. Retina. 2011. PMID: 21836413 Clinical Trial.
-
Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.Br J Ophthalmol. 2006 Jul;90(7):869-74. doi: 10.1136/bjo.2006.090282. Epub 2006 Apr 5. Br J Ophthalmol. 2006. PMID: 16597666 Free PMC article.
-
Ocular photodynamic therapy--standard applications and new indications (part 1). Review of the literature and personal experience.Ophthalmologica. 2007;221(4):216-26. doi: 10.1159/000101922. Ophthalmologica. 2007. PMID: 17579286 Review.
-
The Role of Multifocal Electroretinography in the Assessment of Drug-Induced Retinopathy: A Review of the Literature.Ophthalmic Res. 2016;56(4):169-177. doi: 10.1159/000446321. Epub 2016 Jun 29. Ophthalmic Res. 2016. PMID: 27351191 Review.
Cited by
-
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.BMC Ophthalmol. 2015 Jun 30;15:66. doi: 10.1186/s12886-015-0061-8. BMC Ophthalmol. 2015. PMID: 26122636 Free PMC article.
-
Long-term treatment response after intravitreal bevacizumab injections for patients with central serous chorioretinopathy.PLoS One. 2020 Sep 8;15(9):e0238725. doi: 10.1371/journal.pone.0238725. eCollection 2020. PLoS One. 2020. PMID: 32898167 Free PMC article.
-
Dynamics of retinal function after multiple photodynamic therapies in age-related macular degeneration: a report of cases.Doc Ophthalmol. 2005 Nov;111(3):135-48. doi: 10.1007/s10633-005-5319-7. Epub 2006 Mar 6. Doc Ophthalmol. 2005. PMID: 16523231
-
A pH-responsive silica-metal-organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries.J Control Release. 2020 Aug 10;324:194-203. doi: 10.1016/j.jconrel.2020.04.052. Epub 2020 May 5. J Control Release. 2020. PMID: 32380204 Free PMC article.
-
Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.BMC Ophthalmol. 2017 Aug 10;17(1):140. doi: 10.1186/s12886-017-0535-y. BMC Ophthalmol. 2017. PMID: 28797227 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical